Tech Company Financing Transactions
Grin Therapeutics Funding Round
On 5/28/2025, Grin Therapeutics raised $140 million in Series D funding from Angelini Ventures and Blackstone.
Transaction Overview
Company Name
Announced On
5/28/2025
Transaction Type
Venture Equity
Amount
$140,000,000
Round
Series D
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
Undisclosed
New York, NY Undisclosed
USA
New York, NY Undisclosed
USA
Phone
Website
Email Address
Not Recorded
Overview
GRIN Therapeutics is advancing promising research and development to assess the safety and efficacy of the investigational therapy radiprodil for the treatment of serious neurodevelopmental disorders including GRIN-related disorders, tuberous sclerosis complex (TSC), and focal cortical dysplasia (FCD).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Deborah Dunsire
Chief Executive Officer
Bruce Leuchter
Chief Medical Officer
Russell Chin
Chief Medical Officer
Michael Panzara
Vice President
Walter Lunsmann
VP - Bus. Development
Kenneth Hess
VP - Bus. Development
Jason Lettiere
VP - Finance
Elliott Ruiz
VP - Marketing
Michael Lieberman
VP - Operations
Bob Macnair
VP - Operations
Megan Weaver
VP - Regulatory Affairs
Anne-Marie Li-Kwai-Cheung
Browse more venture capital transactions:
Prev: 5/28/2025: BlockSpaces venture capital transaction
Next: 5/28/2025: Cerby venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document funding rounds that are announced publicly. All VC database entries reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs